Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria AJ Thompson, BL Banwell, F Barkhof, WM Carroll, T Coetzee, G Comi, ...
The Lancet Neurology 17 (2), 162-173, 2018
6556 2018 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis CH Polman, PW O'Connor, E Havrdova, M Hutchinson, L Kappos, ...
New England Journal of Medicine 354 (9), 899-910, 2006
4005 2006 Particle-flow reconstruction and global event description with the CMS detector CMS collaboration
Journal of Instrumentation 12 (10), P10003, 2017
2824 2017 Observation of a new boson with mass near 125 GeV in pp collisions at and 8 TeV S Chatrchyan, V Khachatryan, AM Sirunyan, A Tumasyan, W Adam, ...
Journal of High Energy Physics 2013 (6), 1-127, 2013
2166 2013 Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. F Barkhof, M Filippi, DH Miller, P Scheltens, A Campi, CH Polman, ...
Brain: a journal of neurology 120 (11), 2059-2069, 1997
1801 1997 Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis RJ Fox, DH Miller, JT Phillips, M Hutchinson, E Havrdova, M Kita, M Yang, ...
New England Journal of Medicine 367 (12), 1087-1097, 2012
1559 2012 A controlled trial of natalizumab for relapsing multiple sclerosis DH Miller, OA Khan, WA Sheremata, LD Blumhardt, GPA Rice, ...
New England Journal of Medicine 348 (1), 15-23, 2003
1559 2003 A longitudinal study of abnormalities on MRI and disability from multiple sclerosis PA Brex, O Ciccarelli, JI O'Riordan, M Sailer, AJ Thompson, DH Miller
New England Journal of Medicine 346 (3), 158-164, 2002
1200 2002 Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis LK Fisniku, PA Brex, DR Altmann, KA Miszkiel, CE Benton, R Lanyon, ...
Brain 131 (3), 808-817, 2008
1177 2008 Standardization of M-mode echocardiographic left ventricular anatomic measurements RB Devereux, EM Lutas, PN Casale, P Kligfield, RR Eisenberg, ...
Journal of the American College of Cardiology 4 (6), 1222-1230, 1984
1046 1984 Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes L Kappos, CH Polman, MS Freedman, G Edan, HP Hartung, DH Miller, ...
Neurology 67 (7), 1242-1249, 2006
1016 2006 Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis D Miller, F Barkhof, X Montalban, A Thompson, M Filippi
The Lancet Neurology 4 (5), 281-288, 2005
943 2005 Measurement of the inelastic proton-proton cross section at TeV AM Sirunyan, A Tumasyan, W Adam, F Ambrogi, E Asilar, T Bergauer, ...
Journal of High Energy Physics 2018 (7), 1-33, 2018
924 * 2018 Differential diagnosis of suspected multiple sclerosis: a consensus approach DH Miller, BG Weinshenker, M Filippi, BL Banwell, JA Cohen, ...
Multiple Sclerosis Journal 14 (9), 1157-1174, 2008
924 2008 ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis X Montalban, R Gold, AJ Thompson, S Otero-Romero, MP Amato, ...
Multiple Sclerosis Journal 24 (2), 96-120, 2018
908 2018 Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain K Schmierer, F Scaravilli, DR Altmann, GJ Barker, DH Miller
Annals of neurology 56 (3), 407-415, 2004
878 2004 McAlpine's multiple sclerosis D McAlpine, A Compston
Elsevier Health Sciences, 2005
851 2005 Central nervous system sarcoidosis—diagnosis and management JP Zajicek, NJ Scolding, O Foster, M Rovaris, J Evanson, IF Moseley, ...
Qjm 92 (2), 103-117, 1999
846 1999 Diagnosis of multiple sclerosis: progress and challenges WJ Brownlee, TA Hardy, F Fazekas, DH Miller
The Lancet 389 (10076), 1336-1346, 2017
834 2017 Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance DH Miller, F Barkhof, JA Frank, GJM Parker, AJ Thompson
Brain 125 (8), 1676-1695, 2002
817 2002